AKTX - Akari Therapeutics, Plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.7500
+0.0600 (+3.55%)
As of 2:46PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.6900
Open1.6900
Bid1.7300 x 800
Ask1.7500 x 800
Day's Range1.6900 - 1.7500
52 Week Range1.5600 - 9.2000
Volume50,195
Avg. Volume1,119,535
Market Cap35.709M
Beta (3Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga

    The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...

  • Benzinga

    The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck

    Notwithstanding the ESMO conference generating some huge moves in some stocks, last week turned out to be a muted one for biotechs. A few FDA approvals came through, with Puma Biotechnology Inc (NASDAQ: ...

  • How Much Cash Is Left In The Bank For Akari Therapeutics, Plc (NASDAQ:AKTX)?
    Simply Wall St.

    How Much Cash Is Left In The Bank For Akari Therapeutics, Plc (NASDAQ:AKTX)?

    As the US$39m market cap Akari Therapeutics, Plc (NASDAQ:AKTX) released another year of negative earnings, investors...

  • Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease
    Zacks

    Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

    The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

  • Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
    Zacks

    Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

    Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.

  • Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease
    Zacks

    Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease

    The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 30, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Ulta Beauty Inc (NASDAQ: ULTA ) shares were ...

  • Benzinga

    Akari's 2-Day Rally: What You Need To Know

    Akari Therapeutics PLC (NASDAQ: AKTX ) shares are on track to reclaim the $2 level for the first time since mid-August thanks to two doses of positive tidings from the company. Shares of the nanocap biotech ...

  • The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation
    Benzinga

    The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ...

  • MarketWatch

    Akari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopan

    Akari Therapeutics PLC shares soared 13% in premarket trade Friday, after the company said it has won U.S. Food and Drug Administration Orphan Drug Designation for nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), a rare disorder. The designation comes after the FDA granted nomacopan Fast Track Designation, which means the regulator will accelerate the approval process. "The granting of orphan drug designation and Fast Track designation by the FDA for nomacopan underscores the significant unmet medical need in this disease," said Clive Richardson, Akari chief executive, in a statement. Shares have gained 22.9% in 2019, while the S&P 500 has gained 16.6%.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 15, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Pivotal Software (NYSE: PVTL ) shares were ...

  • Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today
    InvestorPlace

    Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today

    Some recent biopharma news concerning Akari Therapeutics has AKTX stock flying high on Wednesday.Source: Shutterstock The biopharma news has to do with Akari Therapeutics (NASDAQ:AKTX) getting Fast Track designation from the U.S. Food & Drug Administration (FDA) for one of its treatments. This allows the company to speed up testing of the drug. The designation is typically given to medicine with potential to treat illnesses that don't already have wide coverage.The Fast Track designation from the FDA is for Akari Therapeutics' nomacopan. This is the company's drug for treating HSCT-TMA. HSCT-TMA is an orphan condition with an estimated fatality rate of more than 80% in children that suffer from it. There currently isn't an approved treatment for this illness.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe positive biopharma news for AKTX stock comes after the successful treating of two patients in the U.S. with nomacopan. With these results and the FDA's approval, the company is now planning to launch a clinical trial of the treatment in the fourth quarter of 2019. * 15 Growth Stocks to Buy for the Long Haul "We see HSCT-TMA as a gateway into a range of other poorly treated orphan TMAs in both pediatric and adult patients, and are optimistic about the potential for nomacopan to offer an improved standard of care for these orphan conditions with high mortality rates," Clive Richardson, interim CEO of Akari Therapeutics, said in a statement.AKTX stock was up 32% as of Wednesday morning and is up 7% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 As of this writing, William White did not hold a position in any of the aforementioned securities.The post Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today appeared first on InvestorPlace.

  • MarketWatch

    Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation

    Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its treatment (nomacopan) of stem-cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients was granted "Fast Track" designation by the U.S. Food and Drug Administration. Trading volume swelled to 1.7 million shares, compared with the full-day average of about 96,000 shares. A Fast Track designation helps facilitate the development and expedite the review of new drugs for the treatment of serious or life-threatening conditions that address unmet medical needs. ""Fast Track designation provides our HSCT-TMA clinical program a pathway for an expedited approval for nomacopan, and we plan to commence a pivotal trial in the fourth quarter of 2019," said Chief Executive Clive Richardson. The stock has tumbled 42% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 2.9% and the S&P 500 has tacked on 3.2%.

  • Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility
    Simply Wall St.

    Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility

    Anyone researching Akari Therapeutics, Plc (NASDAQ:AKTX) might want to consider the historical volatility of the share...

  • Alexion's Ultomiris Receives EU Approval for PNH in Adults
    Zacks

    Alexion's Ultomiris Receives EU Approval for PNH in Adults

    Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.

  • Alexion Receives FDA Approval for Label Expansion of Soliris
    Zacks

    Alexion Receives FDA Approval for Label Expansion of Soliris

    Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

  • Alexion's sBLA for Ultomiris Gets Priority Review From FDA
    Zacks

    Alexion's sBLA for Ultomiris Gets Priority Review From FDA

    The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

  • Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
    Zacks

    Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study

    Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

  • Benzinga

    Akari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation

    Akari announced positive results for Part A of a Phase 1/2 study dubbed TRACKER that evaluated the safety and efficacy of its topical nomacopan in moderate to severe atopic keratoconjunctivitis. The secondary objective of efficacy was assessed using a standard composite scoring system. Atopic keratoconjunctivitis is a serious corneal and eye surface disease which ultimately leads to visual impairment.

  • Benzinga

    The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...

  • Benzinga

    Microcap Biotech Akari Rallies On Coversin Trial Results

    Akari Therapeutics PLC (NASDAQ: AKTX ) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month. What Happened The microcap biotech — which focuses on therapies for ...

  • What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?
    Simply Wall St.

    What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?

    Every investor in Akari Therapeutics, Plc (NASDAQ:AKTX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...

  • Benzinga

    The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...

  • Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
    Zacks

    Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up

    Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.